La Enfermedad de Fabry en pacientes en hemodiálisis, valoración del tratamiento enzimático sustitutivo

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Diálisis y Trasplante

• Publication date

  2012-07-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/J.DIALIS.2011.11.002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Enzyme replacement therapy and Fabry nephropathy.

  2010cited by this paper
• NF-kappaB in renal inflammation.

  2010cited by this paper
• Frequency of Fabry disease in male and female haemodialysis patients in Spain

  2010cited by this paper
• Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment

  2009cited by this paper
• Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study.

  2009cited by this paper
• Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.

  2008cited by this paper
• Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease

  2008cited by this paper
• [Dialysis and transplant. Spain in 2005].

  2008cited by this paper
• Informe de Situación de Diálisis y Trasplante en España, 2005

  2007cited by this paper
• Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.

  2007cited by this paper
• Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.

  2007cited by this paper
• Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

  2007cited by this paper
• [Effect of renin-angiotensin system in Fabry disease associated proteinuria].

  2007cited by this paper
• Efecto del bloqueo del sistema renina-angiotensina en la proteinuria asociada a la enfermedad de Fabry

  2007cited by this paper
• A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population.

  2006cited by this paper
• The Relationship of Vascular Glycolipid Storage to Clinical Manifestations of Fabry Disease: A Cross-Sectional Study of a Large Cohort of Clinically Affected Heterozygous Women

  2005cited by this paper
• Chronic renal failure, dialysis, and renal transplantation in Anderson-Fabry disease.

  2004cited by this paper
• Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

  2004cited by this paper
• Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.

  2003cited by this paper
• Renal ultrastructural findings in Anderson-Fabry disease.

  2002cited by this paper
• Natural History of Fabry Renal Disease: Influence of α-Galactosidase A Activity and Genetic Mutations on Clinical Course

  2002cited by this paper
• Patients with Fabry disease on dialysis in the United States.

  2002cited by this paper
• Enzyme replacement therapy in Fabry disease

  2001cited by this paper
• Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

  2001cited by this paper
• Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry.

  1996cited by this paper

• Genotype-Phenotype Variations of Renal Complications in Fabry Disease Q279X Mutation

  2020cites this paper